Stockreport

Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement

Rallybio Corporation  (RLYB) 
PDF – Data Support the Study of RLYB116 as a Potential Best-In-Class Therapeutic for Multiple Complement Mediated Diseases –– Initiation of RLYB116 Phase 2 Clinical Trial in [Read more]